Skip to main content
TipRanks
Go Ultimate75% OFF

Dexcom (DXCM) AI Stock Analysis

4,488 Followers
DXCM

Dexcom

(NASDAQ:DXCM)

Select Model
Rating:73Outperform
Price Target:$89.00â–²(9.06% Upside)
Action:reiterated
Date:10/30/26

Score is driven primarily by strong financial performance and a bullish earnings call (raised guidance and margin expansion). Offsetting these positives, technical indicators are weak with the stock trading below key moving averages and negative MACD, and valuation remains premium with a ~30.9 P/E and no dividend yield provided.

Positive Factors
Recurring CGM RevenueDexcom’s sensor replacement cycle creates recurring revenue and supports customer retention after initial adoption. This model provides a durable base for forecasting, while ongoing reimbursement, channel access, and connected-care partnerships can expand utilization and deepen the value of each customer relationship.
Negative Factors
Weaker Cash ConversionRecent deterioration in cash conversion means reported earnings are translating into less incremental cash than before. Although absolute cash generation remains substantial, higher investment or working-capital needs could reduce funding available for expansion, buybacks, and other capital-allocation priorities.

Dexcom Key Performance Indicators (KPIs)

Revenue by SegmentShows how revenue is distributed across different business segments, highlighting which areas are driving growth and which may need strategic attention.

$0.00$250.00M$500.00M$750.00M$1.00B$1.25BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25
Chart Insights

DexCom's Sensor and Other segment shows strong growth momentum, with recent quarters reflecting significant revenue increases. This aligns with the earnings call, which highlights robust revenue growth and strategic expansions, particularly in type 2 diabetes CGM coverage. However, the Hardware segment is experiencing a decline, possibly due to quality and deployment issues with the G7 sensor. Despite these challenges, DexCom's strategic innovations like the Smart Basal and successful product launches such as Stelo are driving positive sentiment and long-term growth prospects.

Data provided by:The Fly

Dexcom (DXCM) vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%50%60%DXCM+39.70%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$30.44B
Dividend Yield
―
Average Volume (3M)
4.23M
Price to Earnings (P/E)
31.6
Beta (1Y)
1.16
Revenue Growth
13.03%
EPS Growth
40.88%
Country
US
Employees
11,050
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Dexcom Business Overview & Revenue Model

Company Description

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individua...

How the Company Makes Money

Dexcom primarily makes money by selling CGM products and related supplies on a recurring-use model. Its core revenue stream is the sale of disposable CGM sensors that must be replaced regularly, creating repeat, ongoing demand from existing users. Ad...

Dexcom Earnings Call Summary

Earnings Call Date:Oct 29, 2026(Q3-2026)|% Change Since:2.10%|Next Earnings Date:Feb 11, 2027
Earnings Call SentimentPositive

The call was strongly positive. Dexcom reported 11% worldwide revenue growth, 14% U.S. growth, continued market-share gains, near-record new patient starts, significant gross-margin and EBITDA-margin expansion, strong cash generation, raised operating and EBITDA margin guidance, and substantial progress in clinical evidence, product launches, manufacturing, and future access expansion. The main challenges were slower international growth, near-term Ireland ramp effects, incremental foreign-exchange headwinds, higher operating expenses, and the loss of preferred access under a PBM representing less than 4% of U.S. revenue. Highlights significantly outweighed the lowlights.

Positive Updates

Third-Quarter Revenue Growth
Worldwide third-quarter revenue was $1.34 billion versus $1.21 billion in the third quarter of 2025, representing 11% growth on both a reported and organic basis.

Negative Updates

Slower International Revenue Growth
International revenue increased 5% on both a reported and organic basis to $375 million. Management said growth was affected by lapping multiple reimbursement wins from the second half of 2025 and expects international revenue to normalize back to higher organic growth levels at the start of next year.

Company Guidance

Dexcom updated full year revenue guidance to be in the range of $5.20 billion to $5.25 billion, representing growth of 12% to 13% for the year, with midpoint fourth quarter growth of 10%; it maintained full year non-GAAP gross profit margin guidance at approximately 64% and increased non-GAAP operating profit margin guidance to approximately 24% and adjusted EBITDA margin guidance to approximately 32%. Dexcom expects to convert nearly 50% of its U.S. customer base to G7 15 Day by year-end, expects CMS to announce a type 2 non-insulin coverage decision this year with coverage taking effect middle of next year, and is still targeting GA for either launching at the end of next year or early '28, depending on regulatory review time lines.

Dexcom Financial Statement Overview

Summary

Strong overall fundamentals: accelerating TTM revenue to $5.10B, solid profitability (~63% gross margin, ~19% net margin), and improved leverage (debt-to-equity ~0.53). The main offset is weakening cash conversion and momentum, with free cash flow down meaningfully in the latest TTM and operating cash flow below net income.

Income Statement

90Very Positive

Balance Sheet

82Very Positive

Cash Flow

74Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue5.10B4.66B4.03B3.62B2.91B2.45B
Gross Profit3.24B2.80B2.44B2.29B1.88B1.68B
EBITDA1.55B1.36B945.70M916.70M565.30M377.60M
Net Income991.00M836.30M576.20M541.50M341.20M216.90M
Balance Sheet
Total Assets6.24B6.34B6.48B6.26B5.39B4.93B
Cash, Cash Equivalents and Short-Term Investments1.82B2.00B2.58B2.72B2.46B2.73B
Total Debt1.39B1.39B2.59B2.59B2.15B2.16B
Total Liabilities3.70B3.59B4.38B4.20B3.26B2.89B
Stockholders Equity2.54B2.75B2.10B2.07B2.13B2.04B
Cash Flow
Free Cash Flow1.10B1.08B630.70M511.90M304.70M53.30M
Operating Cash Flow1.41B1.44B989.50M748.50M669.50M442.50M
Investing Cash Flow261.20M536.00M-207.50M-507.20M-521.50M-216.10M
Financing Cash Flow-2.55B-1.69B-734.80M-318.60M-552.50M10.40M

Dexcom Technical Analysis

Technical Analysis SentimentNeutral
Last Price81.61

Price Trends

50DMA84.17Negative
100DMA82.70Negative
200DMA75.12Positive

Market Momentum

MACD-0.66Negative
RSI47.90Neutral
STOCH28.09Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DXCM, the sentiment is Neutral. The current price of 81.61 is above the 20-day moving average (MA) of 81.40, below the 50-day MA of 84.17, and above the 200-day MA of 75.12, indicating a neutral trend. The MACD of -0.66 indicates Negative momentum. The RSI at 47.90 is Neutral, neither overbought nor oversold. The STOCH value of 28.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DXCM.

Dexcom Risk Analysis

Dexcom disclosed 75 risk factors in its most recent earnings report. Dexcom reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We cannot guarantee that the 2025 Share Repurchase Program will be fully consummated or that such program will enhance the long-term value of our share price.Q4, 2025
2.We cannot guarantee that the 2025 Share Repurchase Program will be fully consummated or that such program will enhance the long-term value of our share price.Q3, 2025
3.We cannot guarantee that the 2025 Share Repurchase Program will be fully consummated or that such program will enhance the long-term value of our share price.Q2, 2025

Dexcom Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DXCM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MDTMDT81Outperform$131.60B25.2710.60%2.78%9.77%12.28%
PODDPODD73Outperform$10.08B23.7929.48%―26.46%75.56%
DXCMDXCM73Outperform$30.44B31.6136.50%―13.03%40.88%
ABTABT67Neutral$186.10B39.969.11%2.35%10.00%-66.06%
TNDMTNDM60Neutral$1.29B-26.22-35.61%―6.73%76.54%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SENSSENS50Neutral$597.11M-4.72-186.15%―104.83%-37.15%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DXCMABTPODDMDTTNDMSENSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DXCM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DXCMDexcom81.6121.8836.63%
ABTAbbott Laboratories107.45-15.64-12.71%
PODDInsulet145.29-201.07-58.05%
MDTMedtronic102.885.765.93%
TNDMTandem Diabetes Care18.48-0.26-1.39%
SENSSenseonics Holdings Inc.10.905.2693.26%

Dexcom Corporate Events

Business Operations and StrategyStock BuybackFinancial Disclosures

Dexcom Lifts 2026 Outlook After Strong Q3 Results

Positive
Oct 29, 2026

On October 29, 2026, Dexcom reported third-quarter 2026 results with worldwide revenue up 11% year-over-year to $1.344 billion, improved GAAP and non-GAAP margins, and GAAP net income of $275.1 million, supported by $1.82 billion in cash, cash equiva...

Business Operations and StrategyExecutive/Board Changes

Dexcom Elevates Jereme Sylvain to COO and CFO

Positive
Sep 14, 2026

On September 10, 2026, Dexcom’s board appointed Executive Vice President and Chief Financial Officer Jereme Sylvain to the expanded role of Executive Vice President, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026. H...

Business Operations and StrategyExecutive/Board Changes

Dexcom appoints Glenn Boehnlein to board of directors

Positive
Sep 10, 2026

On September 10, 2026, Dexcom’s Board of Directors expanded its size to thirteen members and appointed veteran medical technology finance executive Glenn S. Boehnlein as an independent director, effective immediately, with his term running until the...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 30, 2026